Bradykinin As a Probable Aspect in Sars-Cov-2 Scenarios: Is Bradykinin Sneaking Out of Our Sight? Publisher Pubmed



Ghahestani SM¹ ; Mahmoudi J² ; Hajebrahimi S^{3, 4} ; Sioofykhojine AB^{3, 5, 6} ; Salehipourmehr H³ ; Sadeghighyassi F³ ; Mostafaei H⁷ Show Affiliations
Source: Iranian Journal of Allergy# Asthma and Immunology Published:2020

Abstract

The new virus SARS-CoV-2 is savagely spreading out over the world. The biologic studies show that the target receptor for the virus might be angiotensin-converting enzyme 2 (ACE2). This peptide is responsible for converting angiotensin II (Ang II), which is a profoundly active peptide, into Ang 1-7 with quite a balancing barbell function. It is emphasized that the direct target of the virus is ACE2 underlining the obvious difference with ACE. Nevertheless, we hypothesized that a back load build up effect on Ang II may usurp the ACE capacity and subsequently leave the bradykinin system unabated. We think there are clinical clues for dry cough and the presumed aggravating role of ACE inhibitors like Captopril on the disease process. Thereby, we speculated that inhibition of bradykinin synthesis and/or blockade of bradykinin B2 receptor using Aprotinin/ecallantide and Icatibant, respectively, may hold therapeutic promise in severe cases and these molecules can be advanced to clinical trials. Copyright ©, May 2020, Iran J Allergy Asthma Immunol. All rights reserved.